Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin

References

• DöhnerHEsteyEHAmadoriSDiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood2010115345347419880497
   PubMed Web of Science ®Google Scholar
• LerchEEspeliVZuccaEPrognosis of acute myeloid leukemia in the general population: data from southern SwitzerlandTumori200995330331019688968
   PubMed Web of Science ®Google Scholar
• BahlASharmaARainaVLong-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, IndiaAsia Pac J Clin Oncol201511324225225639656
   PubMed Web of Science ®Google Scholar
• ShtilAASignal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cellsCurr Drug Targets200121577711465539
   PubMed Web of Science ®Google Scholar
• ZhangJVisserFKingKMBaldwinSAYoungJDCassCEThe role of nucleoside transporters in cancer chemotherapy with nucleoside drugsCancer Metastasis Rev20072618511017345146
   PubMed Web of Science ®Google Scholar
• MataJFScrideliCAQueirozRPCytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemiaBraz J Med Biol Res200639111417142317146554
   PubMed Web of Science ®Google Scholar
• HazraSOrtSKonradMLavieAStructural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analoguesBiochemistry201049316784679020614893
   PubMed Web of Science ®Google Scholar
• ChabnerBAAmreinPCDrukerBJAntineoplastic Agents Texbook of Goodman & Gilman’s The Pharmacological Basis of Therapeutics11th edBruntonLLLazoJSParkerKLNew YorkThe McGraw-Hill Companies Inc200613151403
   Google Scholar
• StamRWden BoerMLMeijerinkJPDifferential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemiaBlood200310141270127612406912
   PubMed Web of Science ®Google Scholar
• KannoSHiuraTOhtakeTCharacterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cellsClin Chim Acta20073771–214414917097625
   PubMed Web of Science ®Google Scholar
• LambaJKCrewsKPoundsSPharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variantsJ Pharmacol Exp Ther2007323393594517855478
   PubMed Web of Science ®Google Scholar
• RatheSKLargaespadaDADeoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell linesLeukemia20102481513151520508618
   PubMed Web of Science ®Google Scholar
• PommierYLeoEZhangHMarchandCDNA topoisomerases and their poisoning by anticancer and antibacterial drugsChem Biol201017542143320534341
   PubMed Web of Science ®Google Scholar
• PogorelčnikBPerdihASolmajerTRecent developments of DNA poisons–human DNA topoisomerase IIα inhibitors–as anticancer agentsCurr Pharm Des201319132474248823363399
   PubMed Web of Science ®Google Scholar
• BowerJJKaracaGFZhouYSimpsonDACordeiro-StoneMKaufmannWKTopoisomerase II alpha maintains genomic stability through decatenation G(2) checkpoint signalingOncogene201029344787479920562910
   PubMed Web of Science ®Google Scholar
• MiyoshiYKurosumiMKurebayashiJPredictive factors for anthracycline-based chemotherapy for human breast cancerBreast Cancer201017210310919657712
   PubMed Web of Science ®Google Scholar
• WangJXuBYuanPTOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacyBreast Cancer Res Treat2012135253153722864769
   PubMed Web of Science ®Google Scholar
• MukherjeeAShehataMMoseleyPRakhaEEllisIChanSTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancerBr J Cancer2010103121794180021063406
   PubMed Web of Science ®Google Scholar
• NikolényiASükösdFKaizerLTumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancerOncology2011803–426927721734419
   PubMed Web of Science ®Google Scholar
• GrandgirardNLy-SunnaramBFerrantDImpact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemiaLeuk Res200428547948615068901
   PubMed Web of Science ®Google Scholar
• DingemansAMWitloxMAStallaertRAvan der ValkPPostmusPEGiacconeGExpression of DNA topoisomerase II alpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancerClin Cancer Res1999582048205810473085
   PubMed Web of Science ®Google Scholar
• MaternaVPlegerJHoffmannULageHRNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic responseGynecol Oncol200494115216015262134
   PubMed Web of Science ®Google Scholar
• CosseJPMichielsCTumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progressionAnticancer Agents Med Chem20088779079718855580
   PubMed Web of Science ®Google Scholar
• KulsoomBShamsiTSAfsarNAMemonZAhmedNHasnainSNBax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?Cancer Manag Res20181040341629535553
   PubMed Web of Science ®Google Scholar
• BurgerHFoekensJALookMPRNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseClin Cancer Res20039282783612576456
   PubMed Web of Science ®Google Scholar
• SuzukiKKazuiTYoshidaMDrug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitroJpn J Clin Oncol199929732333110470656
   PubMed Web of Science ®Google Scholar
• RustumYMPreislerHDCorrelation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapyCancer Res19793914249282940
   PubMed Web of Science ®Google Scholar
• GalmariniCMThomasXCalvoFIn vivo mechanisms of resistance to cytarabine in acute myeloid leukaemiaBr J Haematol2002117486086812060121
   PubMed Web of Science ®Google Scholar
• SpratlinJSanghaRGlubrechtDThe absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinomaClin Cancer Res200410206956696115501974
   PubMed Web of Science ®Google Scholar
• FarrellJJElsalehHGarciaMHuman equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancerGastroenterology2009136118719518992248
   PubMed Web of Science ®Google Scholar
• GreenhalfWGhanehPNeoptolemosJPPancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialJ Natl Cancer Inst20141061djt34724301456
   PubMedGoogle Scholar
• AchiwaHOguriTSatoSMaedaHNiimiTUedaRDeterminants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancerCancer Sci200495975375715471562
   PubMed Web of Science ®Google Scholar
• MurataAAmanoRYamadaNPrognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine aloneWorld J Surg Oncol20131111723710668
   PubMed Web of Science ®Google Scholar
• WuLShiWLiXHigh expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndromeJ Transl Med201614667426944860
   PubMed Web of Science ®Google Scholar
• AbrahamAVaratharajanSKarathedathSRNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemiaPharmacogenomics201516887789026083014
   PubMed Web of Science ®Google Scholar
• VeugerMJHondersMWWillemzeRBargeRMDeoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemiaEur J Haematol200269317117812406011
   PubMed Web of Science ®Google Scholar
• JordanCTGuzmanMLNobleMCancer stem cellsN Engl J Med20062135512531261
   Google Scholar
• Doussis-AnagnostopoulouIAVassilakopoulosTPThymaraITopoisomerase II alpha expression as an independent prognostic factor in Hodgkin’s lymphomaClin Cancer Res20081461759176618347177
   PubMed Web of Science ®Google Scholar
• ArriolaEMorenoAVarelaMPredictive value of HER-2 and Topoisomerase II alpha in response to primary doxorubicin in breast cancerEur J Cancer200642172954296016935488
   PubMed Web of Science ®Google Scholar
• GieselerFGlasmacherAKämpfeDTopoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxinesLeukemia199610Suppl 3S46S49
   PubMedGoogle Scholar
• KimYYoonSKimSJKimJSCheongJWMinYHMyeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplantYonsei Med J201253353053622476996
   PubMed Web of Science ®Google Scholar
• ItonagaHImanishiDWongYFExpression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3BLeukemia20142871459146624457336
   PubMed Web of Science ®Google Scholar